GENE ONLINE|News &
Novel Triple Immunotherapy Combo Rekindles Hope for Pancreatic Cancer Patients
Pancreatic cancer is the third-leading cause of cancer-related deaths in the US. Despite mammoth advancements in improving chemotherapeutic regimens, metastatic pancreatic adenocarcinomas still pose a greater clinical challenge due to dismal prognosis. However, MIT researchers now develop a novel triple immunotherapy combo that could potentially shrink or even eliminate pancreatic tumors.
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
